Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
Clinical trial NCT04259086 · COMPLETED
Trial details
- NCT number
- NCT04259086
- Sponsor
- Revance Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-06
- Primary completion
- 2020-11-02
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.